Rhumbline Advisers Decreases Holdings in Haemonetics Corporation $HAE

Rhumbline Advisers trimmed its stake in Haemonetics Corporation (NYSE:HAE) by 5.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 156,872 shares of the medical instruments supplier’s stock after selling 9,535 shares during the period. Rhumbline Advisers’ holdings in Haemonetics were worth $7,646,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. River Road Asset Management LLC boosted its stake in Haemonetics by 18.7% during the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after buying an additional 260,624 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Haemonetics by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after acquiring an additional 23,257 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Haemonetics by 11.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock worth $51,777,000 after purchasing an additional 111,307 shares during the period. SG Capital Management LLC boosted its stake in shares of Haemonetics by 92.5% during the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH grew its holdings in Haemonetics by 36.2% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock valued at $34,426,000 after purchasing an additional 187,630 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Up 0.9%

Shares of Haemonetics stock opened at $61.24 on Friday. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32. The firm’s 50 day moving average price is $71.94 and its 200-day moving average price is $63.97. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The company has a market cap of $2.85 billion, a P/E ratio of 16.87, a PEG ratio of 1.28 and a beta of 0.28.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $338.97 million during the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. Haemonetics’s revenue was down 2.7% compared to the same quarter last year. During the same period last year, the firm earned $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, sell-side analysts predict that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on HAE shares. Raymond James Financial reaffirmed an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. JPMorgan Chase & Co. increased their target price on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Robert W. Baird set a $81.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Finally, Citigroup cut their price target on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.44.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.